2007
DOI: 10.3324/haematol.11709
|View full text |Cite
|
Sign up to set email alerts
|

Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults

Abstract: We conducted a retrospective analysis of 11 consecutive patients with various autoimmune cytopenias who failed to respond to conventional treatments and received a fixed-dose regimen of rituximab (100 mg weekly for 4 consecutive weeks). Sustained complete responses were achieved in 4 out of 7 patients with idiopathic thrombocytopenic purpura and in 1 patient with autoimmune pancytopenia. A partial response was observed in 1 patient with autoimmune hemolytic anemia. The immunotherapy had no effect in 1 patient … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

5
96
1
7

Year Published

2008
2008
2013
2013

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 124 publications
(109 citation statements)
references
References 10 publications
5
96
1
7
Order By: Relevance
“…In 11 patients with various autoimmune pancytopenia the Authors reported activity in 4/7 patients with ITP, 1/1 with autoimmune pancytopenia, 1/1 with autoimmune hemolytic anemia, while no effect was observed in 1/1 patient with pure red cell aplasia and in 1/1 with autoimmune neutropenia. 22 Data concerning the timing of response were remarkably different to our previous experience 14,16 and with the results of other studies 12,13 with standard dose. It must be remarked, however, that some other groups did not highlight this prompt response in the majority of patients treated with standard dose.…”
Section: Resultscontrasting
confidence: 54%
“…In 11 patients with various autoimmune pancytopenia the Authors reported activity in 4/7 patients with ITP, 1/1 with autoimmune pancytopenia, 1/1 with autoimmune hemolytic anemia, while no effect was observed in 1/1 patient with pure red cell aplasia and in 1/1 with autoimmune neutropenia. 22 Data concerning the timing of response were remarkably different to our previous experience 14,16 and with the results of other studies 12,13 with standard dose. It must be remarked, however, that some other groups did not highlight this prompt response in the majority of patients treated with standard dose.…”
Section: Resultscontrasting
confidence: 54%
“…In one small series sustained complete response was achieved in four of 7 patients (57%) and no infusion reactions were seen [59]. In a slightly larger series overall and complete responses were achieved in 21/28 (75%) and 12/28 (43%) patients respectively [60].…”
Section: Rituximabmentioning
confidence: 87%
“…A low-dose rituximab regimen (100mg weekly for 4 consecutive weeks) has been explored in ITP patients, with encouraging results [59,60]. In one small series sustained complete response was achieved in four of 7 patients (57%) and no infusion reactions were seen [59].…”
Section: Rituximabmentioning
confidence: 99%
“…Additional mechanisms of action have been proposed, including the indirect modulation of T-cell homeostasis [7]. Three noncontrolled studies have reported the efficacy of RTX given at lower doses (100 mg every week for 4 weeks), and have shown good short-term response rates [8][9][10]. In rheumatoid arthritis (RA), RTX has been licensed at a fixed dose (1,000 mg on days 1 and 2), though this arbitrary regimen was chosen by the manufacturer in both phase II and III trials [11].…”
Section: Introductionmentioning
confidence: 99%